Definition of drug-resistant epilepsy: A reappraisal based on epilepsy types.


Journal

Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336

Informations de publication

Date de publication:
May 2022
Historique:
revised: 30 12 2021
received: 01 11 2021
accepted: 29 01 2022
pubmed: 8 2 2022
medline: 6 4 2022
entrez: 7 2 2022
Statut: ppublish

Résumé

To re-assess the definition of drug-resistant epilepsy based on the evidence from a large-scale, long-term study including both adults and children. We categorized the patients as idiopathic generalized epilepsies (IGEs), focal epilepsies, or structural-metabolic-genetic generalized epilepsies [symptomatic generalized epilepsies (SGEs)] and provided the definition of drug-resistance based on the epilepsy types of the patients. This was a longitudinal study of a prospectively developed and maintained database. All patients with an electro-clinical diagnosis of IGE, focal epilepsy, or SGE, who received treatment from 2008 to 2021, were recruited at the outpatient epilepsy clinic at Shiraz University of Medical Sciences, Shiraz, Iran. All patients had to be followed at our center for at least 24 months. The receiver operating characteristic curve (ROC curve) was used for the statistical analysis. The included patients were as follows: 523 with focal epilepsy, 218 with IGE, and 211 with SGE. For all epilepsy types, the ROC curves of the number of appropriately prescribed antiseizure medications (ASMs) were acceptable indicators to anticipate drug-resistance. The best cutoff point for focal epilepsies was at 4 ASMs (sensitivity: 0.56, specificity: 0.81); for IGE, at 3 ASMs (sensitivity: 0.51, specificity: 0.80); and for SGEs, at 4 ASMs (sensitivity: 0.78, specificity: 0.58). The definition of drug-resistant epilepsy should be different in various epilepsy types. It is the time for the scientific community to reappraise the definition of drug-resistant epilepsy in the light of the new evidence that has become available in the past 11 years since the previously published definition.

Identifiants

pubmed: 35130355
doi: 10.1111/ane.13595
doi:

Substances chimiques

Anticonvulsants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

627-632

Subventions

Organisme : Shiraz University of Medical Sciences
ID : 12345

Informations de copyright

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017;88:296-303.
Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: New advances. Lancet. 2015;385:884-898.
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548-1554.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-521.
Asadi-Pooya AA, Sperling MR. Antiepileptic drugs: A clinician’s manual, 2nd ed. Oxford University Press; 2016.
https://www.ilae.org/guidelines/definition-and-classification/ilae-classification-of-the-epilepsies-2017. Accessed on 30 December 2021.
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069-1077.
https://en.wikipedia.org/wiki/Receiver_operating_characteristic. Accessed on 30 December 2021.
Engel J Jr, McDermott MP, Wiebe S, et al. Early Randomized Surgical Epilepsy Trial (ERSET) Study Group. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012;307:922-930.
Russo A, Hyslop A, Gentile V, et al. Early vagus nerve stimulator implantation as a main predictor of positive outcome in pediatric patients with epileptic encephalopathy. Epileptic Disord. 2021;23:563-571.
Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol. 2006;13:277-282.
Pelliccia V, Deleo F, Gozzo F, et al. Early and late epilepsy surgery in focal epilepsies associated with long-term epilepsy-associated tumors. J Neurosurg. 2017;127:1147-1152.
Holthausen H, Pieper T, Kudernatsch M. Towards early diagnosis and treatment to save children from catastrophic epilepsy - focus on epilepsy surgery. Brain Dev. 2013;35:730-741.
Gesche J, Khanevski M, Solberg C, Beier CP. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies. Epilepsia. 2017;58:e64-e69.
Cerulli Irelli E, Morano A, Barone FA, et al. Persistent treatment resistance in genetic generalized epilepsy: A long-term outcome study in a tertiary epilepsy center. Epilepsia. 2020;61:2452-2460.
Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol. 2007;62:375-381.
Choi H, Hayat MJ, Zhang R, et al. Drug-resistant epilepsy in adults: Outcome trajectories after failure of two medications. Epilepsia. 2016;57:1152-1160.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
Blond BN, Hirsch LJ, Mattson RH. Misperceptions on the chance of seizure freedom with antiseizure medications after two failed trials. Epilepsia. 2020;61:1789-1790.
Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279-286.
Wiebe S. Definition of drug-resistant epilepsy: is it evidence based? Epilepsia. 2013;54(Suppl 2):9-12.
Asadi-Pooya AA, Nikseresht A, Yaghoubi E, Nei M. Physical injuries in patients with epilepsy and their associated risk factors. Seizure. 2012;21:165-168.
Sperling MR, Barshow S, Nei M, Asadi-Pooya AA. A reappraisal of mortality after epilepsy surgery. Neurology. 2016;86:1938-1944.
Landazuri PX, Ulloa CM. The challenges of continued antiseizure medicine trials. Epilepsia. 2020;61:2613-2614.

Auteurs

Ali A Asadi-Pooya (AA)

Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Mohsen Farazdaghi (M)

Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH